

**TOXICOLOGICAL PROFILE FOR
1,3-BUTADIENE**

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Agency for Toxic Substances and Disease Registry

September 2012

DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.

UPDATE STATEMENT

A Toxicological Profile for 1,3-Butadiene, Draft for Public Comment was released in September 2009. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences (proposed)
Environmental Toxicology Branch (proposed)
1600 Clifton Road NE
Mailstop F-62
Atlanta, Georgia 30333

This page is intentionally blank.

FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for the toxic substances each profile describes. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with a public health statement that describes, in nontechnical language, a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. A health effects summary describes the adequacy of information to determine a substance's health effects. ATSDR identifies data needs that are significant to protection of public health.

Each profile:

- (A) Examines, summarizes, and interprets available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects;
- (B) Determines whether adequate information on the health effects of each substance is available or being developed to determine levels of exposure that present a significant risk to human health of acute, subacute, and chronic health effects; and
- (C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are federal, state, and local health professionals; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR's assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staff of the Centers for Disease Control and Prevention and other federal scientists also have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.



Christopher J. Portier, Ph.D.
Assistant Administrator

Agency for Toxic Substances and Disease Registry

*Legislative Background

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to "...effectuate and implement the health related authorities" of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the National Priorities List, in an effort to "...establish and maintain inventory of literature, research, and studies on the health effects of toxic substances" under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.

Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene (prehospital) and hospital medical management of patients exposed during a hazardous materials incident. Volumes I and II are planning guides to assist first responders and hospital emergency department personnel in planning for incidents that involve hazardous materials. Volume III—*Medical Management Guidelines for Acute Chemical Exposures*—is a guide for health care professionals treating patients exposed to hazardous materials.

Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.

Other Agencies and Organizations

The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, injury, and disability related to the interactions between people and their environment outside the workplace. Contact: NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015.

The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational diseases and injuries, responds to requests for assistance by investigating problems of health and safety in the workplace, recommends standards to the Occupational Safety and Health Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains professionals in occupational safety and health. Contact: NIOSH, 200 Independence Avenue, SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 • Phone: 800-35-NIOSH.

The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for biomedical research on the effects of chemical, physical, and biologic environmental agents on human health and well-being. Contact: NIEHS, PO Box 12233, 104 T.W. Alexander Drive, Research Triangle Park, NC 27709 • Phone: 919-541-3212.

Referrals

The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics in the United States to provide expertise in occupational and environmental issues. Contact: AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 • FAX: 202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page: <http://www.aoec.org/>.

The American College of Occupational and Environmental Medicine (ACOEM) is an association of physicians and other health care providers specializing in the field of occupational and environmental medicine. Contact: ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk Grove Village, IL 60007-1030 • Phone: 847-818-1800 • FAX: 847-818-9266.

CONTRIBUTORS

CHEMICAL MANAGER(S)/AUTHOR(S):

Annette Ashizawa, Ph.D.
Nickolette Roney, M.P.H.
Pamela G. Tucker, M.D.
Carolyn Harper, Ph.D.
Diana Cronin
ATSDR, Division of Toxicology and Human Health Sciences (proposed), Atlanta, GA

Lisa Ingerman, Ph.D., DABT
Julie Klotzbach, Ph.D.
Gary L. Diamond, Ph.D.
Mike Lumpkin, Ph.D.
Daniel J. Plewak, B.S.
SRC, Inc., North Syracuse, NY

THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:

1. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying end points.
2. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs sections to assure consistency across profiles and adherence to instructions in the Guidance.
4. Green Border Review. Green Border review assures the consistency with ATSDR policy.

This page is intentionally blank.

PEER REVIEW

A peer review panel was assembled for 1,3-butadiene. The panel consisted of the following members:

1. Sherif Abdel-Rahman, Ph.D., Department of Preventative Medicine and Community Health, University of Texas Medical Branch, Galveston, Texas
2. Genevieve Matanoski, M.D., Dr.PH, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, Maryland
3. Amir Sapkota, Ph.D., Maryland Institute for Applied Environmental Health, University of Maryland, School of Public Health, College Park, Maryland

These experts collectively have knowledge of 1,3-butadiene's physical and chemical properties, toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and quantification of risk to humans. All reviewers were selected in conformity with the conditions for peer review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer reviewers' comments and determined which comments will be included in the profile. A listing of the peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their exclusion, exists as part of the administrative record for this compound.

The citation of the peer review panel should not be understood to imply its approval of the profile's final content. The responsibility for the content of this profile lies with the ATSDR.

This page is intentionally blank.

CONTENTS

DISCLAIMER	ii
UPDATE STATEMENT	iii
FOREWORD	v
QUICK REFERENCE FOR HEALTH CARE PROVIDERS.....	vii
CONTRIBUTORS	ix
PEER REVIEW	xi
CONTENTS.....	xiii
LIST OF FIGURES	xvii
LIST OF TABLES	xix
1. PUBLIC HEALTH STATEMENT.....	1
1.1 WHAT IS 1,3-BUTADIENE?.....	1
1.2 WHAT HAPPENS TO 1,3-BUTADIENE WHEN IT ENTERS THE ENVIRONMENT?.....	2
1.3 HOW MIGHT I BE EXPOSED TO 1,3-BUTADIENE?	2
1.4 HOW CAN 1,3-BUTADIENE ENTER AND LEAVE MY BODY?	3
1.5 HOW CAN 1,3-BUTADIENE AFFECT MY HEALTH?	3
1.6 HOW CAN 1,3-BUTADIENE AFFECT CHILDREN?.....	4
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO 1,3-BUTADIENE?.....	4
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 1,3-BUTADIENE?.....	5
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH?.....	5
1.10 WHERE CAN I GET MORE INFORMATION?.....	6
2. RELEVANCE TO PUBLIC HEALTH	7
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO 1,3-BUTADIENE IN THE UNITED STATES.....	7
2.2 SUMMARY OF HEALTH EFFECTS	8
2.3 MINIMAL RISK LEVELS (MRLs).....	10
3. HEALTH EFFECTS	19
3.1 INTRODUCTION	19
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE.....	19
3.2.1 Inhalation Exposure	20
3.2.1.1 Death.....	20
3.2.1.2 Systemic Effects.....	21
3.2.1.3 Immunological and Lymphoreticular Effects	39
3.2.1.4 Neurological Effects	40
3.2.1.5 Reproductive Effects.....	40
3.2.1.6 Developmental Effects.....	42
3.2.1.7 Cancer	42
3.2.2 Oral Exposure	46
3.2.3 Dermal Exposure.....	47
3.3 GENOTOXICITY.....	47
3.4 TOXICOKINETICS	55
3.4.1 Absorption.....	55
3.4.1.1 Inhalation Exposure	55
3.4.1.2 Oral Exposure	56
3.4.1.3 Dermal Exposure.....	56

3.4.2	Distribution	56
3.4.2.1	Inhalation Exposure	56
3.4.2.2	Oral Exposure	57
3.4.2.3	Dermal Exposure.....	57
3.4.3	Metabolism	57
3.4.4	Elimination and Excretion	62
3.4.4.1	Inhalation Exposure	62
3.4.4.2	Oral Exposure	63
3.4.4.3	Dermal Exposure.....	63
3.4.5	Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models	64
3.5	MECHANISMS OF ACTION.....	85
3.5.1	Pharmacokinetic Mechanisms.....	85
3.5.2	Mechanisms of Toxicity.....	87
3.5.3	Animal-to-Human Extrapolations.....	89
3.6	TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS	90
3.7	CHILDREN'S SUSCEPTIBILITY	91
3.8	BIOMARKERS OF EXPOSURE AND EFFECT.....	92
3.8.1	Biomarkers Used to Identify or Quantify Exposure to 1,3-Butadiene.....	93
3.8.2	Biomarkers Used to Characterize Effects Caused by 1,3-Butadiene	95
3.9	INTERACTIONS WITH OTHER CHEMICALS.....	96
3.10	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	97
3.11	METHODS FOR REDUCING TOXIC EFFECTS	98
3.11.1	Reducing Peak Absorption Following Exposure	98
3.11.2	Reducing Body Burden.....	99
3.11.3	Interfering with the Mechanism of Action for Toxic Effects.....	99
3.12	ADEQUACY OF THE DATABASE.....	99
3.12.1	Existing Information on Health Effects of 1,3-Butadiene.....	100
3.12.2	Identification of Data Needs	100
3.12.3	Ongoing Studies.....	108
4.	CHEMICAL AND PHYSICAL INFORMATION.....	111
4.1	CHEMICAL IDENTITY	111
4.2	PHYSICAL AND CHEMICAL PROPERTIES	111
5.	PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL	114
5.1	PRODUCTION.....	115
5.2	IMPORT/EXPORT.....	119
5.3	USE.....	119
5.4	DISPOSAL	120
6.	POTENTIAL FOR HUMAN EXPOSURE	121
6.1	OVERVIEW	121
6.2	RELEASES TO THE ENVIRONMENT	123
6.2.1	Air	124
6.2.2	Water.....	129
6.2.3	Soil.....	129
6.3	ENVIRONMENTAL FATE.....	130
6.3.1	Transport and Partitioning	130
6.3.2	Transformation and Degradation	131
6.3.2.1	Air	131
6.3.2.2	Water.....	132

6.3.2.3	Sediment and Soil	133
6.3.2.4	Other Media	133
6.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT	133
6.4.1	Air	133
6.4.2	Water.....	134
6.4.3	Sediment and Soil	134
6.4.4	Other Environmental Media.....	137
6.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE.....	137
6.6	EXPOSURES OF CHILDREN	141
6.7	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES	142
6.8	ADEQUACY OF THE DATABASE	142
6.8.1	Identification of Data Needs	143
6.8.2	Ongoing Studies.....	145
7.	ANALYTICAL METHODS.....	146
7.1	BIOLOGICAL MATERIALS	147
7.2	ENVIRONMENTAL SAMPLES	148
7.3	ADEQUACY OF THE DATABASE	150
7.3.1	Identification of Data Needs	151
7.3.2	Ongoing Studies.....	152
8.	REGULATIONS, ADVISORIES, AND GUIDELINES.....	153
9.	REFERENCES	157
10.	GLOSSARY	185
APPENDICES		
A.	ATSDR MINIMAL RISK LEVELS AND WORKSHEETS	A-1
B.	USER'S GUIDE.....	B-1
C.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS.....	C-1
D.	INDEX	D-1

This page is intentionally blank.

LIST OF FIGURES

3-1. Levels of Significant Exposure to 1,3-Butadiene – Inhalation.....	32
3-2. Metabolism of 1,3-Butadiene	58
3-3. Conceptual Representation of a Physiologically Based Pharmacokinetic (PBPK) Model for a Hypothetical Chemical Substance	66
3-4. Existing Information on Health Effects of 1,3-Butadiene	101
6-1. Frequency of NPL Sites with 1,3-Butadiene Contamination	122

This page is intentionally blank.

LIST OF TABLES

2-1. Summary of Available Chronic Risk Assessment Values for 1,3-Butadiene.....	16
3-1. Levels of Significant Exposure to 1,3-Butadiene – Inhalation.....	22
3-2. Genotoxicity of 1,3-Butadiene <i>In Vitro</i>	48
3-3. Genotoxicity of 1,3 Butadiene <i>In Vivo</i>	49
3-4. Physiological and Chemical Parameters Used in the Johanson and Filser (1993) PBPK Model for 1,3-Butadiene.....	68
3-5. Physiological Parameter Values Used in the Kohn and Melnick (2001) PBPK Model for 1,3-Butadiene.....	70
3-6. Chemical Partition Coefficients Parameter Values Used in the Kohn and Melnick (2001) PBPK Model for 1,3-Butadiene.....	71
3-7. Chemical Metabolism Parameter Values Used in the Kohn and Melnick (2001) PBPK Model for 1,3-Butadiene.....	72
3-8. Physiological and Chemical Parameters Used in the Brochot et al. 2007 PBPK Model for 1,3-Butadiene Humans.....	75
3-9. Physiological Parameters Used in Sweeney et al. (1997) 1,3-Butadiene PBPK Model.....	78
3-10. Partition Coefficients Used in Sweeney et al. (1997) PBPK Model for 1,3-Butadiene.....	79
3-11. Nonenzymatic Reaction Rate Constants Used in Sweeney et al. (1997) PBPK Model for 1,3-Butadiene.....	80
3-12. Metabolism Rate Constants Used in the Sweeney et al. (1997) PBPK Model for 1,3-Butadiene.....	81
3-13. Physiological Parameters Used in the Sweeney et al. (2010) PBPK Model for 1,3-Butadiene in Humans.....	82
3-14. Chemical Partition Coefficients Used in the Sweeney et al. (2010) PBPK Model for 1,3-Butadiene in Humans.....	83
3-15. Chemical Metabolism Parameters Used in the Sweeney et al. (2010) PBPK Model for 1,3-Butadiene in Humans.....	84
4-1. Chemical Identity of 1,3-Butadiene.....	112
4-2. Physical and Chemical Properties of 1,3-Butadiene.....	113
5-1. Companies that Produce 1,3-Butadiene in the United States and Annual Capacities During 2008.....	116

5-2. Facilities that Produce, Process, or Use 1,3-Butadiene	117
6-1. Releases to the Environment from Facilities that Produce, Process, or Use 1,3-Butadiene.....	125
6-2. 1,3-Butadiene Emission Data for 2005.....	127
6-3. 1,3-Butadiene Concentrations in Outdoor Air.....	135
6-4. 1,3-Butadiene Concentrations in Indoor Air	136
6-5. Air Concentrations of 1,3-Butadiene Corresponding to Typical Operations Within a Styrene- Butadiene Rubber (SBR) Plant	140
7-1. Analytical Methods For Determining 1,3-Butadiene in Environmental Samples	149
8-1. Regulations, Advisories, and Guidelines Applicable to 1,3-Butadiene.....	154